1Schindler T;Bornmann W;Pellicena P.Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase[J],2000(5486).
2Beham Schmid C;Apfelbeck U;Sill H.Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis[J],2002(01).
3Druker B J;Sawyers CL;Kantarjian H;etal.Activity of a specific inhibitor of the bcr-abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome[J],2001(14).
4O′Brien SG;Guilhot F;Larson RA.Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia[J],2003(11).
5Kantarjian HM;Talpaz M;Brien S.Imatinib mesylate for Philadelphia chromosome-positive chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results[J],2002(07).
6Topaly J;Zeller W J;Fruehauf S.Synergistic activity of the new abl-specific tyrosine kinase inhibitor ST1-571 and chemotherapeutic drugs on bcrabl-positive chronic myelogenous leukemia cells[J],2001(03).
7Kano Y;Akutsu M;Tsunoda S.In vitro cytotoxic effects of a tyrosine kinase inhibitor ST1-571 in combination with commonly used antileukemic agents,2001(07).
8Thiesing JT;Ohno Jones S;Kolibaba KS.Efficacy of ST1-571 an abl tyrosine kinase inhibitor in conjunction with other antileukemic agents against Bcr-Abl-positive cells,2000(09).
9Kantarjian HM;Talpaz M;Brien S.Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia[J],2003(02).
10Hochhaus A;Kreil S;Corbin AS.Molecular and chromosomal mechanisms of resistance to imatinib(STI571) therapy[J],2002(11).
